Table 1 KRAS mutational profile in NSCLC cells.

From: miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

No.

TheraScreen mutation Ct

TheraScreen mutation

PT#2

N/A

WT

PT#13

N/A

WT

PT#18

N/A

WT

A549

30.4

KRAS c.34G>T

HCC827

N/A

WT

Calu-1

29.7

KRAS c.34G>T

  1. TheraScreen results on primary NSCLC (PT#2, PT#13 and PT#18) and immortalized A549, HCC827 and Calu-1 cell lines.
Back to article page